普伐他汀对原发性高血压伴房颤患者血浆ET、Hs-CRP及血压的影响

目的:探讨普伐他汀对原发性高血压伴房颤患者血浆内皮素(ET)、高敏C反应蛋白(Hs-CRP)及血压的干预作用。方法:200例符合条件标准的原发性高血压合并心房颤动患者,随机分为两组,常规治疗组(100例)主要应用钙拮抗剂、血管紧张素转换酶抑制剂、利尿剂、β受体阻滞剂等药治疗;普伐他汀组(100例)在常规治疗组基础上加用普伐他汀20mg,每晚1次,两组均连续干预3个月;同时选择80例健康体检者作正常组对照。药物治疗前后检测血浆ET、Hs-CRP。结果:原发性高血压伴房颤患者共有178例完成药物干预试验,其中常规治疗组88例,普伐他汀组90例。(1)普伐他汀组及常规治疗组治疗前,ET、Hs-CRP水平均高于正常组(P<0.01)。治疗后,普伐他汀组及常规治疗组ET、Hs-CRP水平较同组治疗前均降低(P<0.01);普伐他汀组较常规治疗组降低更显著(P<0.05)。(2)治疗后,普伐他汀组及常规治疗组血压比同组治疗前均显著降低(P<0.01),普伐他汀组较常规治疗组降低更显著(P<0.05)。结论:原发性高血压伴房颤患者在常规治疗的基础上加用普伐他汀,能进一步降低ET、Hs-CRP及血压水平,改善内皮功能,抑制异常炎性激活,从而减少血栓的形成。

Intervention effects of pravastatin on ET, Hs-CRP and blood pressure in the plasma of primary hypertension patients with atrial fibrillation

Objective: To discusses the intervention effect of pravastatin on endothelin(ET),high sensitive C-reactive protein(Hs-CRP) and blood pressure in the plasma of primary hypertension patients with atrial fibrillation.Methods:A total of 200 standard primary hypertension patients with atrial fibrillation were divided into two groups(conventional treatment and pravastatin treatment) randomly.Patients in conventional group were mainly treated with calcium antagonists,angiotensin converting enzyme inhibitors(ACEI),diuretic and β-receptor blockers.And patients in pravastatin group were treated by pravastatin(20mg,once each night) besides these conventional drugs.The course of treatment were 3 months.ET,Hs-CRP and blood pressure were tested before and after medicine treatment.Results:A total of 178 primary hypertension patients with atrial fibrillation completed this experiment,including 88 with conventional treatment and 90 ones with pravastatin treatment.The levels of ET and Hs-CRP in two groups were all significantly higher than healthy people before treatment(P<0.01).After treatment,the levels of ET and Hs-CRP of these two treatment groups were significantly lower than those before treatment(P<0.01),and the decrease of those with pravastatin was more significant(P<0.05).The blood pressure of two groups were significantly lower after treatment(P<0.01),and the decrease of those with pravastatin treatment was more significant(P<0.05).Conclusions:Treatment with pravastatin on the basis of conventional treatment,can reduce blood pressure,ET,Hs-CRP and blood pressure of patients with primary hypertension,improve endothelium function which will prevent abnormal inflammatory and thrombosis.